KTTAW Company Profile and Key Details

NASDAQ : KTTAW

Pasithea Therapeutics

$0.00

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Pasithea Therapeutics Corp. (KTTAW) stock remained unchanged at $0.00 a share on NASDAQ. The stock opened at $0.01, fluctuating between $0.00 to $0.01 during the session.

Stock Snapshot

0.0035

Prev. Close

26.05K

Market Cap

0.0035

Day Low

N/A

P/E Ratio

-1.58

EPS (TTM)

-12.18

Cash Flow per Share

0.01

Open

7.44M

Number of Shares

0.0122

Day High

98.54%

Free Float in %

22.46

Book Value

52.82K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Sep 09, 2026	0.00	0.00	0.00	0.00	52.82K
Sep 02, 2026	0.00	0.01	0.00	0.01	10.9K
Aug 31, 2026	0.00	0.00	0.00	0.00	30K
Aug 25, 2026	0.01	0.01	0.01	0.01	1.06K
Aug 24, 2026	0.01	0.01	0.01	0.01	1.2K
Aug 21, 2026	0.01	0.01	0.01	0.01	46
Aug 18, 2026	0.01	0.01	0.01	0.01	42K
Aug 13, 2026	0.01	0.01	0.01	0.01	902
Aug 12, 2026	0.01	0.01	0.01	0.01	350
Aug 10, 2026	0.01	0.01	0.00	0.00	15.23K
Aug 07, 2026	0.00	0.01	0.00	0.00	24.24K
Aug 05, 2026	0.00	0.01	0.00	0.01	37.22K
Aug 04, 2026	0.01	0.01	0.01	0.01	400
Aug 03, 2026	0.01	0.01	0.01	0.01	12.8K
Jul 28, 2026	0.01	0.01	0.01	0.01	302
Jul 27, 2026	0.01	0.01	0.01	0.01	28.7K
Jul 23, 2026	0.01	0.01	0.01	0.01	200
Jul 22, 2026	0.01	0.01	0.01	0.01	10.97K
Jul 21, 2026	0.01	0.01	0.01	0.01	2.51K
Jul 20, 2026	0.01	0.01	0.01	0.01	880

Contact Details

Miami Beach, FL 33139

United States

https://www.pasithea.com 702 514 4174

About Company

Pasithea Therapeutics Corp. is a biotechnology firm dedicated to exploring and developing therapies for various psychiatric and neurological conditions. Beyond its research endeavors, the company intends to establish clinics specializing in the treatment of depression. At these facilities, certified pharmacists will administer intravenous ketamine infusions, and the firm will also extend business support services for these operations. Founded in 2020, Pasithea Therapeutics Corp. maintains its corporate headquarters in Miami Beach, Florida.

Stock Peers

ARGX

-18.27-1.82%

argenx SE$984.04 REGN

-14.39-1.78%

Regeneron Pharmaceuticals, Inc.$793.26 MDGL

-13.54-2.48%

Madrigal Pharmaceuticals, Inc.$533.12 VRTX

-6.56-1.26%

Vertex Pharmaceuticals Incorporated$514.56 UTHR

-2.96-0.58%

United Therapeutics Corporation$503.86 KRYS

-2.54-0.73%

Krystal Biotech, Inc.$345.55 ONC

-9.2-2.62%

BeOne Medicines AG$341.80 PRAX

-6.73-1.95%

Praxis Precision Medicines, Inc.$338.57 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 LGND

1.2+0.42%

Ligand Pharmaceuticals Incorporated$289.25

Company Overview

The stock is currently trading near its 52-week low $0.00 and $0.01. With a market capitalization of about $26.05 thousand, Pasithea Therapeutics Corp. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.29). Key stats such as the average daily volume over the past year has been around 11.02 thousand shares, trading with heavier-than-usual volume. Headquartered in Miami Beach, FL, Pasithea Therapeutics Corp. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Tiago Reis Marques, the company employs approximately 5 people and listed since September 15, 2021. Pasithea Therapeutics Corp. is a biotechnology firm dedicated to exploring and developing therapies for various psychiatric and neurological conditions.

Technical Performance

KTTAW has shown sold momentum, gaining 108.57% over the past week and 14.29% over the past quarter, though year-to-date performance is up 14.29%. Average 10-day trading volume of 31.86 thousand shares is significantly above the 3-month average of 12.44 thousand, indicating heightened recent market interest.

Valuation Metrics

Pasithea Therapeutics Corp. trades at a P/E ratio of -0.22, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.08 suggesting the stock is closer to book value. The P/FCF stands at -1.03, also above market averages.

Dividend & Fair Value

Pasithea Therapeutics Corp. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $13.25. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Pasithea Therapeutics Corp. earnings surprise history is a mixed track record. The quarter that ended August 14, 2026, missed forecasts by 0.0%. The prior quarter beat by -73.33%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in February 25, 2026.

Financial & Profitability Overview

Over the trailing twelve months, Pasithea Therapeutics has not generated any revenue. Returns are negative, with ROA at -61.12% and ROE at -68.22%.
On valuation metrics, Pasithea Therapeutics trades at a P/E of -0.22, P/S of 0.00 and P/B of 0.08. The current ratio is 26.25 and quick ratio is 26.25. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -1418.20 days , indicating it collects cash faster than it pays suppliers.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Pasithea Therapeutics posted revenue of $0.00, down slightly from $486.56K in the prior quarter. Gross profit was - $648.45K (margin 0.00%). Operating income was - $15.98M (margin 0.0%). Net income was- $15.96M (EPS - $13.01).
The company ended the quarter with $16.33M in cash and short-term investments, a total debt of $81.68K, and net debt of - $16.25M. Total assets were $26.12M, with equity of $23.40M. Financials further reflected weakness, with operating cash flow of - $13.43M, free cash flow of - $13.46M, and capital expenditures of - $34.30K.

Price Forecast & Outlook

Our AI price prediction model suggests that Pasithea Therapeutics Corp. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 185.71%, with price expected at $0.01 by November 24, 2023, within a range of $0.01 to $0.02

Key Takeaways

Pasithea Therapeutics Corp. (NASDAQ:KTTAW) shares are up 14.29% year-to-date Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Pasithea Therapeutics Corp. trading at a premium to the broader market with a P/E of -0.22.

Frequently Asked Questions

What is the current Pasithea Therapeutics Corp. (KTTAW) stock price?

Pasithea Therapeutics Corp. (NASDAQ: KTTAW) stock price is $0.00 in the last trading session. During the trading session, KTTAW stock reached the peak price of $0.01 while $0.00 was the lowest point it dropped to. The percentage change in KTTAW stock occurred in the recent session was 0% while the dollar amount for the price change in KTTAW stock was $0.00.

KTTAW's industry and sector of operation?

The NASDAQ listed KTTAW is part of Biotechnology industry that operates in the broader Healthcare sector. Pasithea Therapeutics Corp. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of KTTAW?

No Data

How KTTAW did perform over past 52-week?

KTTAW's closing price is 0% higher than its 52-week low of $0.00 where as its distance from 52-week high of $0.01 is -71.31%.

How many employees does KTTAW have?

Number of KTTAW employees currently stands at 5.

Link for KTTAW official website?

Official Website of KTTAW is: https://www.pasithea.com

How do I contact KTTAW?

KTTAW could be contacted at phone 702 514 4174 and can also be accessed through its website. KTTAW operates from 1111 Lincoln Road, Miami Beach, FL 33139, United States.

How many shares of KTTAW are traded daily?

KTTAW stock volume for the day was 52.82K shares. The average number of KTTAW shares traded daily for last 3 months was 11.02K.

What is the market cap of KTTAW currently?

The market value of KTTAW currently stands at $26.05K with its latest stock price at $0.00 and 7.44M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	5
Beta	0.29
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

KTTAW Company Profile and Key Details

Pasithea Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Earnings & Analyst Outlook

Company Overview

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Technical Performance

Key Takeaways

Price Forecast & Outlook

Valuation Metrics